Drugs / MUC1 Peptide-Poly-ICLC Vaccine
MUC1 Peptide-Poly-ICLC Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03300817 | Dec 2017 → Sep 2021 overdue | lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT02134925 | Jun 2014 → Jan 2017 overdue | colorectal carcinoma, colorectal tubulovillous adenoma | National Cancer Institute (NCI) | Active not recruiting | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUC1 Peptide-Poly-ICLC Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03300817 ↗ |
| Known as | MUC1 peptide vaccine with adjuvant | “To compare the immunogenicity at week 12 of a MUC1 peptide vaccine with adjuvant (MUC1 peptide-poly-ICLC adjuvant vaccine) (administered at 0, 2, and 10 weeks)” NCT02134925 ↗ |
| Known as | MUC1 peptide-poly-ICLC adjuvant vaccine | “This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps...” NCT02134925 ↗ |
| Action | Deplete | “Vaccines made from peptides may help the body build an effective immune response to kill polyp cells.” NCT02134925 ↗ |
| Modality | Vaccine | “MUC1 peptide-poly-ICLC adjuvant vaccine” NCT02134925 ↗ |
| Route | Subcutaneous | “Given SC” NCT02134925 ↗ |
| Target | MUC1 | “anti-MUC1 antibody response” NCT02134925 ↗ |